Thus, our results on the effects of pitavastatin treatment on total adiponectin concentrations in patients with T2DM and dyslipidemia are consistent with those of previous studies showing that pitavastatin does not increase adiponectin levels [33,34]. The gene discussed is ADIPOQ; the disease is metabolic syndrome.